Mechanical circulatory support in cardiogenic shock

European Heart Journal

Volumn 35, Issue 3, 2014, Pages 156-167

  Werdan, Karl ^a   Gielen, Stephan ^a   Ebelt, Henning ^a   Hochman, Judith S ^b  

^a MARTIN LUTHER UNIVERSITÄT HALLE WITTENBERG   (Germany)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

APACHE II score; Cardiogenic shock; Interleukin 6 (IL 6); Left ventricular assist devices; Mortality

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; CALCIUM SENSITIZER; CATECHOLAMINE; CYTOKINE; DOBUTAMINE; ENOXIMONE; HYPERTENSIVE FACTOR; INTERLEUKIN 6; LEVOSIMENDAN; MILRINONE; NORADRENALIN; PHOSPHODIESTERASE INHIBITOR;

ACUTE HEART INFARCTION; APACHE; ASSISTED CIRCULATION; BIVENTRICULAR ASSIST DEVICE; CARDIAC POWER INDEX; CARDIOGENIC SHOCK; CARDIOVASCULAR MORTALITY; CENTRIFUGAL PUMP; CONSERVATIVE TREATMENT; EXTRACORPOREAL MEMBRANE OXYGENATION DEVICE; EXTRACORPOREAL OXYGENATION; HEART ARRHYTHMIA; HEART INDEX; HEART LEFT VENTRICLE PRESSURE; HEART MUSCLE OXYGEN CONSUMPTION; HEART MUSCLE REVASCULARIZATION; HEART RIGHT VENTRICLE PRESSURE; HEMODYNAMICS; HUMAN; INTRAAORTIC BALLOON PUMP; LEFT VENTRICULAR ASSIST DEVICE; LONG TERM SURVIVAL; MEDICAL DEVICE COMPLICATION; META ANALYSIS (TOPIC); MULTIPLE ORGAN FAILURE; PNEUMATIC TOOL; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RIGHT VENTRICULAR ASSIST DEVICE; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; SURVIVAL RATE; SYSTEMATIC REVIEW (TOPIC); THERAPY EFFECT;

APACHE II SCORE; CARDIOGENIC SHOCK; INTERLEUKIN 6 (IL-6); LEFT VENTRICULAR ASSIST DEVICES; MORTALITY;

CARDIOTONIC AGENTS; HEART-ASSIST DEVICES; HEMODYNAMICS; HUMANS; INTRA-AORTIC BALLOON PUMPING; MULTIPLE ORGAN FAILURE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SHOCK, CARDIOGENIC; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VASOCONSTRICTOR AGENTS;

EID: 84892740281     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/eht248     Document Type: Review

References (84)

1. Thiele H, Schuler G, Neumann F-J, Hausleiter J, Olbrich H-G, Schwarz B, Hennersdorf M, Empen K, Fuernau G, Desch S, de Waha S, Eitel I, Hambrecht R, Böhm M, Kurowski V, Lauer B, Minden H-H, Figulla H-R, Braun-Dullaeus RC, Strasser RH, Rochor K, Maier SKG, Möllmann H, Schneider S, Ebelt H, Werdan K, Zeymer U. Intraaortic balloon counterpulsation inacute myocardial infarction com-plicatedbycardiogenic shock: design and rationaleofthe Intraaortic Balloon Pump in Cardiogenic Shock II (IABP-SHOCK II) trial. Am Heart J 2012;163:938-945.
2. Hochman JS, Sleeper LA, Webb JG, Sanborn TA, White HD, Talley JD, Buller CE, Jacobs AK, Slater JN, Col J, McKinlay SM, LeJemtel TH. Early revascularization in acute myocardial infarction complicated by cardiogenic shock. SHOCK investigators. Should we emergently revascularize occluded coronaries for cardiogenic shock? N Engl J Med 1999;341:625-634.
3. Hochman JS, Sleeper LA, Webb JG, Dzavik V, Buller CE, Aylward P, Col J, White HD; SHOCK Investigators. Early revascularization and long-term survival in cardiogenic shock complicating acute myocardial infarction. JAMA 2006;295:2511-2515.
4. Thiele H, Zeymer U, Neumann F-J, Ferenc M, Olbrich H-G, Hausleiter J, Richardt G, Hennersdorf M, Empen K, Fuernau G, Desch S, Eitel I, Hambrecht R, Fuhrmann J, Böhm M, Ebelt H, Schneider S, Schuler G, Werdan K, for the IABP-SHOCK II Trial Investigators. Intraaortic balloon support for myocardial infarction with cardiogenic shock. N Engl J Med 2012;367:1287-1296.
5. Reynolds HR, Hochman JS. Cardiogenic shock-current concepts and improving outcomes. Circulation 2008;117:686-697.
6. Sleeper LA, Reynolds HR, White HD, Webb JG, Dzavik V, Hochman JS. A severity scoring system for risk assessment of patients with cardiogenic shock: a report from the SHOCK trial and registry. Am Heart J 2010;160:443-450.
7. Katz JN, Stebbins AL, Alexander JH, Reynolds HR, Pieper KS, Ruzyllo W, Werdan K, Geppert A, Dzavik V, Van de Werf F, Hochman JS, for the TRIUMPH Investigators. Predictors of 30-day mortality in patients with refractory cardiogenic shock following acute myocardial infarction despite a patent infarct artery. Am Heart J 2009;158: 680-687.
8. Kohsaka S, Menon V, Lowe AM, Lange AM, Dzavik V, Sleeper LA, Hochman JS; SHOCK Investigators. Systemic inflammatory response syndrome after acute myo-cardial infarction complicated by cardiogenic shock. Arch Int Med 2005;165: 1643-1650.
9. Kohsaka S, Menon V, Iwato K, Lowe A, Sleeper LA, Hochman JS. Microbiological profile of septic complication in patients with cardiogenic shock following acute myocardial infarction (from the SHOCK Study). Am J Cardiol 2007;99:802-804.
10. Prondzinsky R, Lemm H, Swyter M, Wegener N, Unverzagt S, Carter JM, Russ M, Schlitt A, Buerke U, Christoph A, Schmidt H, Winkler M, Thiery J, Werdan K, Buerke M. Intra-aortic balloon counterpulsation in patients with acute myocardial infarction complicated by cardiogenic shock: the prospective, randomized IABP SHOCK Trial for attenuation of multiorgan dysfunction syndrome. Crit Care Med 2010;38:152-160.
11. Prondzinsky R, Unverzagt S, Lemm H, Wegener N-A, Schlitt A, Heinroth KM, Dietz S, Buerke U, Kellner P, Loppnow H, Fiedler MG, Thiery J, Werdan K, Buerke M. Interleukin-6,-7, and-10 predict outcome in acute myocardial infarction complicated by cardiogenic shock. Clin Res Cardiol 2012;101:375-384.
12. Prondzinsky R, Unverzagt S, Lemm H, Wegener N, Heinroth K, Buerke U, Fiedler M, Thiery J, Haerting J, Werdan K, Buerke M. Acute myocardial infarction and cardio-genic shock-prognostic impact of cytokines: INF-g, TNF-a, MIP-1b, G-CSF, and MCP-1b. Med Klin Intensivmed Notfmed 2012;107:476-484.
13. Hochman JS. Cardiogenic shock complicating acute myocardial infarction: expanding the paradigm. Circulation 2003;107:2998-3002.
14. Fincke R, Hochman JS, Lowe AM, Menon V, Slater JN, Webb JG, LeJemtel TH, Cotter G; SHOCK Investigators. Cardiac power is the strongest hemodynamic correlate ofmortalityin cardiogenic shock: a report from theSHOCK trial registry. J Am Coll Cardiol 2004;44:340-348.
15. Mendoza DD, Cooper HA, Panza JA. Cardiac power output predicts mortality across a broad spectrum of patients with acute cardiac disease. Am Heart J 2007; 153:366-370.
16. Werdan K. Do not get in RAGE in cardiogenic shock: it is detrimental! Crit Care Med 2012;40:1669-1670
17. The Task Force for the Diagnosis, Treatment of Acute, Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012. Eur Heart J 2012;33:1787-1847.
18. Antman EM, Hand M, Armstrong PW, Bates ER, Green LA, Halasyamani LK, Hochman JS, Krumholz HM, Lamas GA, Mullany CJ, Pearle DL, Sloan MA, Smith SC Jr, 2004 Writing Committee Members, Anbe DT, Kushner FG, Ornato JP, Jacobs AK, Adams CD, Anderson JL, Buller CE, Creager MA, Ettinger SM, Halperin JL, Hunt SA, Lytle BW, Nishimura R, Page RL, Riegel B, Tarkington LG, Yancy CW. 2007 focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the Canadian Cardiovascular Society, endorsed by the American Academy of Family Physicians: 2007 Writing Group to review new evidence and update the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction, writing on behalf of the 2004 Writing Committee. Circulation 2008;117:296-329.
19. Samuels LE, Kaufman MS, Thomas MP, Holmes EC, Brockman SK, Wechsler AS. Pharmacological criteria for ventricular assist device insertion following postcardiot-omy shock: experience with the Abiomed BVS system. J Card Surg. 1999;14: 288-293.
20. Russ MA, Prondzinsky R, Christoph A, Schlitt A, Buerke U, Söffker G, Lemm H, Swyter M, Wegener N, Winkler M, Carter JM, Reith S, Werdan K, Buerke M. Hemo-dynamic improvement following levosimendan treatment in patients with acute myocardial infarction and cardiogenic shock. Crit Care Med 2007;35:2732-2739.
21. Garcia-González J, Dominguez-Rodriguez A, Ferrer-Hita JJ, Abreu-Gonzaléz P, Munoz MB. Cardiogenic shock after primary percutaneous coronary intervention: effects of levosimendan compared with dobutamine on haemodynamics. Eur J Heart Fail 2006;8:723-728.
22. Fuhrmann JT, Schmeisser A, Schulze MR, Wunderlich C, Schoen SP, Rauwolf T, Weinbrenner C, Strasser RH. Levosimendan is superior to enoximone in refractory cardiogenic shock complicating acute myocardial infarction. Crit Care Med 2008;36: 2257-2266.
23. Editorial: 2450-2451
24. Comments: 2009:37:1181-1182
25. Erratum 2008;36:2966.
26. Mebazaa A, Nieminen MS, Packer M, Cohen-Solal A, Kleber FX, Pocock SJ, Thakkar R, Padley RJ, Pöder P, Kivikko M; SURVIVE Investigators. Levosimendan vs. dobutamine for patients with acute decompensated heart failure: the SURVIVE randomized trial. JAMA 2007;297:1883-1891.
27. Khan H, Metra M, Blair JE, Vogel M, Harinstein ME, Filippatos GS, Sabbah HN, Porchet H, Valentini G, Gheorghiade M. Istaroxime, a first in class new chemical entity exhibiting SERCA-2 activation and Na-K-ATPase inhibition: a new promising treatment for acute heart failure syndromes? Heart Fail Rev. 2009;14:277-287.
28. Shah SJ, Blair JE, Filippatos GS, Macarie C, Ruzyllo W, Korewicki J, Bubenek-Turconi SI, Ceracchi M, Bianchetti M, Carminati P, Kremastinos D, Grzybowski J, Valentini G, Sabbah HN, Gheorghiade M; HORIZON-HF Investigators. Effects of istaroxime on diastolic stiffness in acute heart failure syndromes: results from the Hemodynamic, Echocardiographic, and Neurohormonal Effects of Istaroxime, a Novel Intravenous Inotropic and Lusitropic Agent: a Randomized Controlled Trial in Patients Hospitalized with Heart Failure (HORIZON-HF) trial. Am Heart J 2009; 157:1035-1041.
29. De Backer D, Biston P, Devriendt J, Madl C, Cochrad D, Aldecoa C, Brasseur A, Defrance P, Gottignies P, Vincent JL; SOAPIIInvestigators. Comparisonofdopamine and norepinephrine in the treatment of shock. N Engl J Med 2010;362:779-789.
30. The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC). ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 2012;33:2569-2619.
31. Werdan K, Ruß M, Buerke M, Delle-Karth G, Geppert A, Schöndube FA. Cardio-genic shock due to myocardial infarction: diagnosis, monitoring and treatment-a German-Austrian S3 Guideline. Dtsch Arztebl Int 2012;109:343-351.
32. Abu-Omar Y, Tsui SSL. Mechanical circulatory support for AMI and cardiogenic shock. J Card Surg 2010;25:434-441.
33. Thiele H, Smalling RW, Schuler GC. Percutaneous left ventricular assist devices in acute myocardial infarction complicated by cardiogenic shock. Eur Heart J 2007; 28:2057-2063.
34. Thiele H, Allam B, Chatellier G, Schuler G, Lafont A. Shock in acute myocardial infarction: the Cape Horn for trials? Eur Heart J 2010;31:1828-1835.
35. Ouweneel DM, Henriques JPS. Percutaneous cardiac support devices for cardio-genic shock: current indications and recommendations. Heart 2012;98:1246-1254.
36. Naidu SS. Novel percutaneous cardiac assist devices: the science of and indications for hemodynamic support. Circulation 2011;123:533-543.
37. Anderson M, Smedira N, Samuels L, Madani M, Naka Y, Acker M, Hout M, Benali K. Use ofthe AB5000ventricular assist devicein cardiogenic shock after acute myocar-dial infarction. Ann Thorac Surg 2010;90:706-712.
38. Stewart GC, Givertz MM. Mechanical circulatory support for advanced heart failure-patients and technology in evolution. Circulation 2012;125:1304-1315.
39. Tayara W, Starling RC, Yamani MH, Wazni O, Jubran F, Smedira N. Improved survival after acute myocardial infarction complicated by cardiogenic shock with circulatory support and transplantation: comparing aggressive intervention with conservative treatment. J Heart Lung Transplant 2006;25:504-509.
40. Wever-Pinzon O, Stehlik J, Kfoury AG, Terrovitis JV, Diakos NA, Charitos C, Li DY, Drakos SG. Ventricular assist devices: pharmacological aspects of a mechanical therapy. Pharmacol Ther 2012;134:189-199.
41. Werdan K, Ruß M, Buerke M. The intra-aortic balloon pump. In Marco Tubaro, Nicolas Danchin, Gerasimos Filippatos, Patrick Goldstein, Pascal Vranckx, Doron Zahger (eds). The ESC Textbook of Intensive and Acute Cardiac Care. Oxford: Oxford University Press; 2011, p. 277-288.
42. Kern MJ, Aguirre FV, Tatineni S, Penick D, Serota H, Donohue T, Walter K. Enhanced coronary bloodflow velocity during intraaortic balloon counterpulsationincritically ill patients. J Am Coll Cardiol 1993;21:359-368.
43. Kern MJ, Aguirre F, Bach R, Donohue T, Siegel R, Segal J. Augmentation of coronary blood flow by intraaortic balloon pumping in patients after coronary angioplasty. Circulation 1993;87:500-511.
44. Kimura A, Toyota E, Songfang L, Goto M, Yada T, Chiba Y, Ebata J, Tachibana H, Ogasawara Y, Tsujioka K, Kajiya F. Effects of intraaortic balloon pumping on septal arterial blood flow velocity waveform during severe left main coronary artery stenosis. J Am Coll Cardiol 1996;27:810-816.
45. Fuchs RM, Brin KP, Brinker JA, Guzman PA, Heuser RR, Yin FCP. Augmentation of regional coronary blood flow by intra-aortic balloon counterpulsation in patients with unstable angina. Circulation 1983;68:1117-1123.
46. Jung C, Rödiger C, Fritzenwanger M, Schumm J, Lauten A, Figulla HR, Ferrari M. Acute microflow changes after stop and restart of intra-aortic balloon pump in car-diogenic shock. Clin Res Cardiol. 2009;98:469-475.
47. den Uil CA, Lagrand WK, van der Ent M, Jewbali LS, Brugts JJ, Spronk PE, Simoons ML. The effects of intra-aortic balloon pump support on macrocirculation and tissue microcirculation in patients with cardiogenic shock. Cardiology 2009;114:42-46.
48. Buerke M, Prondzinsky R, Lemm H, Dietz S, Buerke U, Ebelt H, Bushnaq H, Silber R-E, Werdan K. Intra-aortic balloon counterpulsation in the treatment of infarction-related cardiogenic shock-review of the current evidence. Artif Organs 2012;36:505-511.
49. Zeymer U, Bauer T, Hamm C, Zahn R, Weidinger F, Seabra-Gomes R, Hochadel M, Marco J, Gitt A, Euro Heart Survey PCI Steering Committee: Marco J (Chairman), Eberli F, Gitt A, Seabra-Gomes R, Serruys PW, Silber S, Vahanian A, Weidinger F, Wijns W, Zeymer U. Use and impact of intra-aortic balloon pump on mortality in patients with acute myocardial infarction complicated by cardiogenic shock: results of the Euro Heart Survey on PCI. Euro Intervention 2011;7:437-441.
50. Prondzinsky R, Unverzagt S, Russ M, Lemm H, Swyter M, Wegener N, Buerke U, Raaz U, Ebelt H, Schlitt A, Heinroth K, Haerting J, Werdan K, Buerke M. Hemo-dynamic effects of intra-aortic balloon counterpulsation in patients with acute myo-cardial infarction complicated by cardiogenic shock: the prospective, randomized IABP SHOCK trial. Shock 2012;37:378-384.
51. Sjauw KD, Engström AE, Vis MM, van der Schaaf RJ, Baan J Jr, Koch KT, de Winter RJ, Piek JJ, Tijsen JGP, Henriques JPS. A systematic review and meta-analysis of intraaor-tic balloon pump therapy in ST-elevation myocardial infarction: should we change the guidelines? Eur Heart J 2009;30:459-468.
52. Unverzagt S, Machemer MT, Solms A, Thiele H, Burkhoff D, Seyfarth M, de Waha A, Ohman EM, Buerke M, Haerting J, Werdan K, Prondzinsky R. Intra-aortic balloon pump counterpulsation (IABP) for myocardial infarction complicatedbycardiogenic shock. Cochrane Database Syst Rev 2011;7:CD007398.
53. Bahekar A, Singh M, Singh S, Bhuriya R, Ahmad K, Khosla S, Arora R. Cardiovascular outcomes using intra-aortic balloon pump in high-risk acute myocardial infarction with or without cardiogenic shock: a meta-analysis. J Cardiovasc Pharmacol Therap 2012;17:44-56.
54. Ohman EM, Nanas J, Stomel RJ, Leesar MA, Nielsen DWT, O'Dea D, Rogers FJ, Harber D, Hudson MP, Fraulo E, Shaw LK, Lee KL; TACTICS Trial. Thrombolysis and counterpulsation to improve survival in myocardial infarction complicated by hypotension and suspected cardiogenic shock or heart failure: results of the TACTICS Trial. J Thromb Thrombolysis 2005;19:33-39.
55. TRIUMPH Investigators, Alexander JH, Reynolds HR, Stebbins AL, Dzavik V, Harrington RA, Van de Werf F, Hochman JS. Effect of tilarginine acetate in patients with acute myocardial infarction and cardiogenic shock: the TRIUMPH randomized controlled trial. JAMA 2007;297:1657-1666.
56. Perrera D, Stables R, Thomas M, Booth J, Pitt M, Blackman D, de Belder A, Redwood S, for the BCIS-1 Investigators. Elective intra-aortic balloon counterpulsa-tion during high-risk percutaneous coronary intervention-a randomized controlled trial. JAMA 2010;304:867-874.
57. Patel MR, Smalling RW, Thiele H, Barnhart HX, Zhou Y, Chandra P, Chew D, Cohen M, French J, Perrera D, Ohman EM. Intra-aortic balloon counterpulsation and infarct size in patients with acute anterior myocardial infarction without shock: the CRISP-AMI randomized trial. JAMA 2011;306:1329-1337.
58. Thiele H, Sick P, Boudriot E, Diederich KW, Hambrecht R, Niebauer J, Schuler G. Randomized comparison of intra-aortic balloon support with a percutaneous left ventricular assist device in patients with revascularized acute myocardial infarction complicated by cardiogenic shock. Eur Heart J 2005;26:1276-1283.
59. Burkhoff D, Cohen H, Brunckhorst C, O'Neill WW; Tandem Heart Investigators Group. A randomized multicenter clinical study to evaluate the safety and efficacy of the Tandem Heart percutaneous ventricular assist device vs. conventional therapy with intraaortic balloon pumping for treatment of cardiogenic shock. Am Heart J 2006;152:469.e1-469.e8.
60. Kar B, Gregoric ID, Basra SS, Idelchik GM, Loyalka P. The percutaneous ventricular assist device in severe refractory cardiogenic shock. J Am Coll Cardiol 2011;57: 688-696.
61. O'Gara PT, Kushner FG, Ascheim DD, Casey DE Jr, Chung MK, de Lemos JA, Ettinger SM, Fang JC, Fesmire FM, Franklin BA, Granger CB, Krumholz HM, Linderbaum JA, Morrow DA, Newby LK, Ornato JP, Ou N, Radford MJ, Tamis-Holland JE, Tommaso CL, Tracy CM, Woo YJ, Zhao DX. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2013;127:e362-e425.
62. Thiele H, Lauer B, Hambrecht R, Boudriot E, Cohen HA, Schuler G. Reversal of car-diogenic shock by percutaneous left atrial-to-femoral arterial bypass assistance. Circulation 2001;104:2917-2922.
63. Cheng JM, den Uil CA, Hoeks SE, van der Ent M, Jewbali LSD, van Domburg RT, Serruys PW. Percutaneous left ventricular assist devices vs. intra-aortic balloon pump counterpulsation for treatment of cardiogenic shock: a meta-analysis of controlled trials. Eur Heart J 2009;30:2102-2108.
64. Meyns B, Dens J, Sergeant P, Herijgers P, Daenen W, Flameng W. Initial experiences with the Impella device in patients with cardiogenic shock-Impella support for car-diogenic shock. Thorac Cardiovasc Surg 2003;51:312-317.
65. Lauten A, Engström A, Jung C, Empen K, Erne P, Cook S, Windecker S, Bergmann M, Klingenberg R, Lüscher T, Haude M, Rulands D, Butter C, Ullmann B, Hellgren L, Modena MG, Pedrazzini G, Henriques J, Figulla H, Ferrari M. Percutaneous left ventricular support with the Impella 2. 5 assist deviceinacute cardiogenic shock-results of the Impella EUROSHOCK-Registry. Circ Heart Fail 2013;61:23-30.
66. Seyfarth M, Sibbing D, Bauer I, Fröhlich G, Bott-Flügel L, Byrne R, Dirschinger J, Kastrati A, Schömig A. A randomized clinical trial to evaluate the safety and efficacy of a percutaneous left ventricular assist device vs. intra-aortic balloon pumping for treatment of cardiogenic shock caused by myocardial infarction. J Am Coll Cardiol 2008;52:1584-1588.
67. Engström AE, Cochieri R, Driessen AH, Sjauw KD, Vis MM, Baan J, de Jong M, Lagrand WK, van der Sloot JA, Tijssen JG, de Winter RJ, de Mol BA, Piek JJ, Henriques JP. The Impella 2. 5 and 5. 0 devices for ST-elevation myocardial infarction patients presenting with severe and profound cardiogenic shock: the Academic Medical Center intensive care unit experience. Crit Care Med 2011;39:2072-2079.
68. Siegenthaler MP, Brehm K, Strecker T, Hanke T, Notzold A, Olschewski M, Weynad M, Sievers H, Beyersdorf F. The Impella recover microaxial left ventricular assist device reduces mortality for postcardiotomy failure: a three-center experience. J Thorac Cardiovasc Surg 2004;127:812-822.
69. Jurmann MJ, Siniawski H, Erb M, Drews T, Hetzer R. Initial experience with miniature axial flow ventricular assist devices for postcardiotomy heart failure. Ann Thorac Surg 2004;77:1642-1647.
70. Giesler GM, Gomez JS, Letsou G, Vooletich M, Smalling RW. Initial report of percutaneous right ventricular assist for right ventricular shock secondary to right ventricular infarction. Cath Cardiovasc Interv 2006;68:263-266.
71. Atwater BD, Nee LM, Gimelli G. Long-term survival using intra-aortic balloon pump and percutaneous right ventricular assist device for biventricular mechanical support of cardiogenic shock. J Invasive Cardiol 2008;20:E205-E207.
72. Kawashima D, Gojo S, Nishimura T, Itoda Y, Kitahori K, Motomura N, Morota T, Murakami A, Takamoto S, Kyo S, Ono M. Left ventricular mechanical support with Impella provides more ventricular unloading in heart failure than extracorporeal membrane oxygenation. ASAIOJ 2011;57:169-176.
73. Jung C, Ferrari M, Gradinger R, Fritzenwanger M, Pfeifer R, Schlosser M, Poerner TC, Brehm BR, Figulla HR. Evaluation of the microcirculation during extracorporeal membrane-oxygenation. Clin Hemorheol Microcirc. 2008;40:311-314.
74. Jung C, Lauten A, Roediger C, Fritzenwanger M, Schumm J, Figulla HR, Ferrari M. In vivo evaluation of tissue microflow under combined therapy with extracorporeal life support and intra-aortic balloon counterpulsation. Anaesth Intensive Care 2009;37: 833-835.
75. Sheu JJ, Tsai TH, Lee FY, Fang HY, Sun CK, Leu S, Yang CH, Chen SM, Hang CL, Hsieh YK, Chen CJ, Wu CJ, Yip HK. Early extracorporeal membrane oxygenator-assisted primary percutaneous coronary intervention improved 30-day clinical outcomes in patients with ST-segment elevation myocardial infarction complicated with profound cardiogenic shock. Crit Care Med 2010;38:1810-1817.
76. Asaumi Y, Yasuda S, Morii I, Kakuchi H, Otsuka Y, Kawamura A, Sasako Y, Nakatani T, Nonogi H, Miyazaki S. Favourable clinical outcome in patients with cardiogenic shock due to fulminant myocarditis supported by percutaneous extracorporeal membrane oxygenation. Eur Heart J 2005;26:2185-2192.
77. Doll N, Kiali B, Borger M, Bucerius J, Kramer K, Schmitt DV, Walther T, Mohr FW. Five-year results of 219 consecutive patients treated with extracorporeal membrane oxygenation for refractory postoperative cardiogenic shock. Ann Thorac Surg 2004; 77:151-157.
78. Arlt M, Philipp A, Voelkel S, Camboni D, Rupprecht L, Graf BM, Schmid C, Hilker M. Hand-held minimized extracorporeal membrane oxygenation: a new bridge to recovery in patients with out-of-centre cardiogenic shock. Eur J Cardiothorac Surg 2011;40:689-694.
79. Formica F, Avalli L, Redaelli G, Paolini G. Interhospital stabilization of adult patients with refractory cardiogenic shock by veno-arterial extracorporeal membrane oxygenation. Int J Cardiol 2011;147:164-165.
80. Arlt M, Philipp A, Voelkel S, Schopka S, Husser O, Hengstenberg C, Schmid C, Hilker M. Early experiences with miniaturized extracorporeal life-support in the catheterization laboratory. Eur J Cardiothorac Surg 2012;42:858-863.
81. Stegman BM, Newby LK, Hochman JS, Ohman EM. Post-myocardial infarction cardiogenic shock is a systemic illness in need of systemic treatment. J Am Coll Cardiol 2012;59:644-647.
82. Den Uil CA, Lagrand WK, van der Ent M, Jewbali LSD, Cheng JM, Spronk PE, Simoons ML. Impaired microcirculation predicts poor outcome of patients with acute moycardial infarction complicated by cardiogenic shock. Eur Heart J 2010; 31:3032-3039.
83. Goldberg RJ, Spencer FA, Gore JM, Lessard D, Yarzebski J. Thirty-year trends (1975 to 2005) in the magnitude of, management of, and hospital death rates associated with cardiogenic shock in patients with acute myocardial infarction-a population-based perspective. Circulation 2009;119: 1211-1219.
84. Selejan SR, Poss J, Hewera L, Kazakov A, Bohm M, Link A. Role of receptor for advanced glycation end products in cardiogenic shock. Crit Care Med 2012;40: 1513-1522.